Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
for
Non-Small Cell Lung Cancer,
Location: Montreal, Fairfax VA, Durham NC, Toronto,
Sponsor: AbbVie
Sex: All
Age: 18+
Code: NCT05005403
Phase1, Recruiting
Featured
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer
for
Ovarian Cancer
Location: Fairfax VA, Chicago IL, San Antonio TX, Denver CO,
Sponsor: AbbVie
Sex: All
Age: 18+
Code: NCT07278336
Phase1, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Featured
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
Location: Providence RI, Teaneck NJ, Fairfax VA, Cincinnati OH,
Sponsor: AbbVie
Sex: Female
Age: 18+
Code: NCT07024784
Phase2, Recruiting
Featured
A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine
for
Advanced High-Grade Epithelial Ovarian Cancer,
Location: Worcester MA, Pittsburgh PA, Sarasota FL, Detroit MI,
Sponsor: AbbVie
Sex: Female
Age: 18+
Code: NCT06682988
Phase2, Recruiting
Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy
Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation
Location: Durham NC, Buffalo NY, Rochester MN, Scottsdale AZ,
Sponsor: Merrimack Pharmaceuticals
Sex: All
Age: 18+
Code: NCT03076372
Phase1, Recruiting
A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors
for
Colorectal Cancer, Triple Negative Breast Cancer,
Location: New York NY, Tampa FL, Columbus OH, Atlanta GA,
Sponsor: OncXerna Theraputics, Inc.
Sex: All
Age: 18+
Code: NCT05453825
Phase2, Recruiting
Phase 1, Safety and Tolerability Study of XmAb541 and XmAb808 in Advanced Solid Tumors
for
Ovarian Cancer
Location: The Bronx NY, New York NY, Fort Worth TX,
Sponsor: Xencor, Inc.
Sex: Female
Age: 18+
Code: NCT07593092
Phase1, Recruiting
Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.
for
Ovarian Cancer, Endometrial Cancer,
Location: Boston MA, Fairfax VA, Orlando FL, Nashville TN,
Sponsor: ArriVent BioPharma, Inc.
Sex: Female
Age: 18+
Code: NCT07755436
Phase1, Recruiting
A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer
for
Platinum-resistant Ovarian Cancer
Location: Boston MA, New Haven CT, Fairfax VA, Sarasota FL,
Sponsor: Stemline Therapeutics, Inc.
Sex: Female
Age: 18+
Code: NCT07226427
Phase1, Recruiting
A Study of Lorigerlimab in Participants With Advanced Solid Tumors
for
Platinum-resistant Ovarian Cancer,
Location: Montreal, Toronto, Pittsburgh PA, Grand Rapids MI,